Tango Therapeutics

Tango Therapeutics company information, Employees & Contact Information

Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Tango was launched in 2017 with a $55 million Series A investment from Third Rock Ventures. The company has established a robust product engine that leverages advances in DNA sequencing and CRISPR-based target discovery to generate breakthrough medicines that have the potential to provide deeper, more sustained benefit than today’s targeted therapies, and extend the benefit of available immuno-oncology agents. Tango Therapeutics is focused on three areas of drug development, each in well-defined patient populations currently lacking effective treatment options, and each with hallmarks of cancer that have not been targeted yet. These include: loss of tumor suppressor gene function; multiple oncogenic drivers; and immune evasion. What fuels each of Tango’s programs is an increasingly sophisticated ability to utilize synthetic lethality - the interaction between two genes that causes cell death when both are inactivated. In cancer cells, one of these genes is inactivated by mutation; the other will be inactivated by a drug. This approach leaves normal cells largely unaffected, with the potential to greatly enhance anti-tumor efficacy and reduce associated toxicity. Tango’s success will be driven by its depth of understanding of the genetic subtypes of cancer, and corresponding insights into novel drug targets and combinations uniquely relevant to each subtype. By shaping discovery efforts in this way, Tango has the potential to reach the clinic quickly, and with a clear plan for identifying the patients most likely to benefit from each new treatment, an approach that could increase both speed and probability of success in translating novel target discoveries into transformational new medicines for patients.

Company Details

Employees
168
Founded
-
Address
201 Brookline Ave,
Phone
(857) 320-4900
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Boston, Massachusetts
Looking for a particular Tango Therapeutics employee's phone or email?

Tango Therapeutics Questions

News

Tango Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference - GlobeNewswire

Tango Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference GlobeNewswire

Tango Therapeutics to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025 - GlobeNewswire

Tango Therapeutics to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025 GlobeNewswire

Leading Biotech Tango Therapeutics CEO Barbara Weber to Share Company Updates at 2025 Cantor Conference - Stock Titan

Leading Biotech Tango Therapeutics CEO Barbara Weber to Share Company Updates at 2025 Cantor Conference Stock Titan

Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights - Business Wire

Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights Business Wire

Development of a Commercial Ready Process for TNG908: A Potent, Selective, and Brain-Penetrant MTA-Cooperative PRMT5 Inhibitor - ACS Publications

Development of a Commercial Ready Process for TNG908: A Potent, Selective, and Brain-Penetrant MTA-Cooperative PRMT5 Inhibitor ACS Publications

Tango Therapeutics to Present First Clinical Data from TNG260 at Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025 - The Manila Times

Tango Therapeutics to Present First Clinical Data from TNG260 at Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025 The Manila Times

Tango Therapeutics Earnings Alert: Q2 2025 Results Coming August 5 Without Investor Call - Stock Titan

Tango Therapeutics Earnings Alert: Q2 2025 Results Coming August 5 Without Investor Call Stock Titan

Discovery of TNG908: A Selective, Brain Penetrant, MTA-Cooperative PRMT5 Inhibitor That Is Synthetically Lethal with MTAP-Deleted Cancers - ACS Publications

Discovery of TNG908: A Selective, Brain Penetrant, MTA-Cooperative PRMT5 Inhibitor That Is Synthetically Lethal with MTAP-Deleted Cancers ACS Publications

Top Tango Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant